Previous Close | 10.74 |
Open | 11.31 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 11.31 - 11.31 |
52 Week Range | 10.62 - 17.00 |
Volume | |
Avg. Volume | 3,480 |
Market Cap | 20.279B |
Beta (5Y Monthly) | 0.28 |
PE Ratio (TTM) | 565.50 |
EPS (TTM) | 0.02 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.52 (4.64%) |
Ex-Dividend Date | Mar 28, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for ALPMF
Astellas Pharma US, Inc. (TSE: 4503, President: Mark Reisenauer, "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug and pediatric exclusivity to CRESEMBA® (isavuconazonium sulfate) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients. On December 8, 2023, CRESEMBA for injection was approved for pediatric patients 1 year of age and older and capsules for pediatric patients 6 years of age and older w
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced dosing of the first patient in the STARLIGHT™ 2 Phase 3 pivotal study for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of vasomotor symptoms (VMS) associated with menopause in Japanese women.
Kelonia will receive $40 million upfront through the partnership, and could receive $35 million more if Astellas opts into another program.